Abola, M. V. & Prasad, V. JAMA Internal Medicine. Published online February 01, 2016
This study reviewed transcripts of meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration to characterize potential financial and other conflicts of interest of public speakers.
The Oncologic Drugs Advisory Committee advises the US Food and Drug Administration (FDA) about medications for the treatment of cancer. The committee’s meeting agenda typically includes presentations by both a company seeking marketing approval for an oncologic drug that it sponsors and by the FDA, as well as a public hearing for comments by other speakers. Speakers may be patients with cancer or may represent patient advocacy organizations, and speakers are asked to disclose financial associations with the sponsoring company or other relevant financial associations.
Read the abstract here